Potent Narcotic ‘Lollipop’ Becomes Best Seller_WSJ
Off-label prescribing of drugs for unapproved uses puts consumers at high risk of harm–but it is the single most lucrative marketing strategy.
-
-
Conflicts of Interest Hopkins Study: Researchers Don’t Want to Disclose $$
Two surveys confirm medical researchers' resistance to complying with conflict of interest disclosure requirements.
-
Medicine In Conflict:Financial Tentacles in Cardiology_Business Week
Business Week reports: "From 1986 to 2003 the number of nonsurgical cardiac procedures, such as propping open arteries with wire-mesh stents, rose twelve fold, according to the American Heart Association.
-
NIMH to Screen Studies for Science and Human Risks – Science
Jan 22, 1999 SCIENCE Volume 283, Number 5401, 22 Jan 1999, pp. 464 – 465 BIOETHICS NIMH to Screen Studies for Science and Human Risks Eliot Marshall For more than a year, patient activists and ethicists have been calling for a revolution in the way clinical studies in psychiatry are…
-
Bioethics Debate: Ethics of U Penn surgical “drug implant” experiment
Bioethics Debate: Ethics of U Penn Surgical “Drug Implant” Experiment This debate between AHRP President, Vera Sharav and Bioethicist, Paul Root Volpe, Ph.D., University of Pennsylvania, was prompted by an October 7 infomail. The reasons for AHRP’s opposition to drug implants for psychiatric patients are explained here: https://ahrp.org/ahrpspeaks/drugimplant1103.php —–Original Message—–…
-
US Gov Pesticide Exposure Experiments: Target Children–$970 per child – Wash Post
US Gov Pesticide Exposure Experiments: Target Children–$970 per child – Wash Post Wed, 3 Nov 2004 The Washington Post reports (below) that the Environmental Protection Agency (EPA) announced plans to enroll 60 young children in Duval County, Florida – infants to age 3 – exposing them to pesticides to study…
-
GSK Sales Reps told NOT to Divulge Paxil Data / Merck Withdraws Vioxx
GSK Sales Reps told NOT to Divulge Paxil Data / Merck Withdraws Vioxx Thu, 30 Sep 2004 The Associated Press reports: “Merck pulled Vioxx after admitting studies showed the drug raised the risk of heart attack. As recently as August, Merck “strongly” disagreed with studies showing the drug increased heart…
-
Article
From: “VERACARE” To: “Dr. Bart Campbell” Subject: RE: AHRP Response to criticism re: fatal ARDS lung experiment Date: Tue, 1 Jul 2003 ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) https://ahrp.org//testimonypresentations/ARDSNet0603/sharav.html
-
OHRP Compliance Letters
ETHICAL AND POLICY ISSUES IN RESEARCH INVOLVING HUMAN PARTICIPANTS National Bioethics Advisory Commitee (NBAC) Final Report, 2001 Exhibit 3.1: Office of Protection from Research Risks (OPRR) Compliance Oversight Investigations Resulting in Restrictions/Actions to Institutions that have Multiple Project Assurances (MPA) between January 1990 – June 2000 Year, Institution and Action…
-
Article
AIDS Drug Trial report–Slipshod Journalism– NY Times Sat, 23 Jul 2005 Please join our effort to tweak the New York Times to practice what their banner states: “All the News that’s fit to print” That surely means fair and balanced reporting about contentious issues that pit the weak and vulnerable…
-
Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry?
Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Fri, 19 Dec 2003 Carl Elliott is a clear eyed academic who teaches bioethics at the University of Minnesota . He is currently a visiting associate professor at School of Social Sciences at the Institute for Advanced Study at Princeton….
-
Government Investigations, 1990 – 2001
Government Investigations 1990 to August 2001 National Bioethics Advisory Committee Report: ETHICAL AND POLICY ISSUES IN RESEARCH INVOLVING HUMAN PARTICIPANTS, 1998 Exhibit 3.1: Office of Protection from Research Risks (OPRR) Compliance Oversight Investigations Resulting in Restrictions/Actions to Institutions that have Multiple Project Asssurances (MPA) between January 1990 – June 2000…